Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder

Arpamas Seetasith,1 Mallik Greene,2 Ann Hartry,3 Chakkarin Burudpakdee1 1Medical and Scientific Services, Real-World Evidence Solutions, IQVIA, Falls Church, VA 22042, USA; 2Health Economics and Outcomes Research, Otsuka Pharmaceutical Development And Commercialization, Inc., Princeton, NJ 08540, USA; 3Health Economics and Outcomes Research, Lundbeck, Deerfield, IL 60015, USACorrespondence: Chakkarin BurudpakdeeIQVIA, 3110 Fairview Park Drive, Suite 400, Falls Church, VA 22042, USATel +1 610 244 2025Email cburudpakdee@yahoo.comPurpose: Major depressive disorder (MDD) is a chronic mental disorder with a substantial clinical and economic burden. Despite the efficacy of adjunctive atypical antipsychotics (AAP) for augmentation in patients with major depressive disorder (MDD) who failed first-line antidepressant therapy (ADT), little is known of the impact of AAP choices on healthcare resource use and costs in real-world practice. Therefore, this study compared real-world healthcare utilization and costs in patients with MDD treated with brexpiprazole or extended-release (XR) quetiapine as adjunctive treatment to ADT.Patients and methods: Adults with MDD starting adjunctive treatment with brexpiprazole (n=844) or extended-release (XR) quetiapine (n=688) were identified in the adjudicated health plan claims data (07/2014 – 09/2016). Resource use and healthcare costs in the 6 months following treatment initiation were compared between non-matched populations, and between propensity score-matched groups, and by multivariable regression analyses.Results: During follow-up, unadjusted all-cause hospitalization (6.6% vs 12.5%) and ED visits (17.0% vs 27.5%) were lower with brexpiprazole compared to quetiapine XR (both p